Pharmacovigilance (PV) and medical information (MI) are complementary components of an effective compliance framework. While they serve distinct operational roles, strong coordination between them supports consistent safety management across the product lifecycle. Regulators expect every safety signal to be captured, processed, and communicated consistently, from the first clinical trial through market entry and continuing for as long as the product remains on the market.
Mature compliance infrastructures can also support investor confidence by demonstrating organizational readiness and disciplined risk management. An integrated approach to PV and MI outsourcing provides this assurance without overextending internal teams. Biotech companies can meet global compliance expectations, scale support as pipelines grow, and maintain predictable costs. All this can be achieved by combining drug safety oversight with structured medical information services, while leadership remains focused on advancing development and securing market access.
Scalability without distraction
As your pipeline grows, safety reporting volumes rise, medical inquiries multiply, and regulatory expectations expand with every new geography. Building parallel teams for pharmacovigilance and medical information internally locks capital into fixed overhead and slows execution.
With PV and MI outsourcing, scale follows your pipeline. Scalable PV solutions allow case processing and MI response functions to expand or contract with the pipeline. For executives, it’s a safeguard that protects both timelines and reputation.
Scalability snapshot
| Building In-House | PV + MI Outsourcing | |
| Speed | Months to recruit, train, validate | Weeks to activate validated systems |
| Cost | Fixed overhead, regardless of activity | Flexible, activity-based spend |
| Capacity | Limited ability to adjust | Scales up/down with pipeline stage |
| Focus | Leadership tied to compliance build-out | Leadership focused on development & partnerships |
Compliance insurance
Picture your team preparing for its first EMA inspection. An adverse event report is requested. The regulator expects it immediately, in the correct format, logged in the right database, traceable to the exact medical inquiry that triggered it. Could your current systems deliver that on demand?
The EMA’s 2024 annual report noted a continued increase in pharmacovigilance inspections across the EU, reflecting heightened scrutiny of compliance systems.¹ PV and MI outsourcing can strengthen inspection preparedness by supporting structured processes, experienced oversight, and validated systems.
The result? Less time worrying about audits and more time keeping development on track.
¹ EMA Annual Report 2024
Cost efficiency that scales with you
As an executive, you already know that the budget you commit early must justify itself to both regulators and investors. Building permanent pharmacovigilance and medical information teams means fixed overhead long before revenue arrives. That’s capital locked into compliance infrastructure instead of advancing your pipeline.
Deloitte’s 2024 Global Life Sciences Outlook found that more than 60% of life sciences leaders now prioritize cost flexibility as a top operational goal.² The reason is simple: markets and pipelines shift too quickly to carry permanent teams for functions that could scale with demand.
With PV and MI outsourcing, spending follows milestones. As patient exposure increases, so does the volume of safety reporting. Individual Case Safety Reports (ICSRs), which are submitted in the global E2B(R3) electronic format, grow in direct relation to patients enrolled and products used.³ Outsourcing ensures these peaks are managed efficiently, without locking in fixed costs.
² Deloitte, Global Life Sciences Outlook 2024
³ EMA, EU Individual Case Safety Report (ICSR) Implementation Guide, 2021
Biomapas: Turning complexity into control
When biotech companies prepare for regulatory submissions or expand into new markets, they often face the same challenge: fragmented systems, heavy manual work, and rising compliance demands. Biomapas addresses these challenges by providing PV and MI outsourcing as an integrated solution that reduces risk while increasing efficiency.
“The biggest challenge is always finding solutions that can adapt to the requirements and needs of companies regardless of their size, capacity, or finances,” says Olga Asimaki, VP, Global Safety and Medical Information at Biomapas. “That is especially true with today’s increasingly complex medical therapies.”
Through integrated PV and MI outsourcing, Biomapas delivers a single, compliant framework for managing safety cases, medical inquiries, and product quality complaints.
The results:
- Compliance strengthened through a single source of truth system.
- Efficiency gains across teams, with less manual work and fewer errors.
- Faster responses to medical inquiries and safety cases, boosting confidence during audits and inspections.
- Higher motivation internally, and greater trust from clients and regulators.
Executive takeaway: Biomapas’ proven track record demonstrates how PV and MI outsourcing transform compliance into a scalable, data-driven advantage that protects timelines and fosters investor confidence.
Beyond compliance: Strategic advantages
With the right approach, PV and MI outsourcing can be a strategic advantage:
- No delays at market entry – Established PV and MI infrastructures help organizations enter new markets with greater operational readiness, reducing the risk of compliance-related delays.
- Trust in diverse regions – localized medical information services build trust among healthcare professionals and patients, ensuring engagement aligns with cultural and regulatory expectations.
- Investor-ready infrastructure – inspection-ready systems and visible compliance maturity strengthen fundraising and partnership discussions.
- Leadership focus preserved – expert teams manage compliance proactively, while internal leadership stays concentrated on science, growth strategy, and partnerships.
Conclusion
In conclusion, PV and MI are opportunities to demonstrate maturity and control, as when outsourced together, they can start acting as a growth enabler.
For many growing biotechs, the strategic question is not simply whether to outsource PV and MI, but how to design a model that supports sustainable compliance while preserving organizational focus on development. At Biomapas, we help biotechs do exactly that.
If your PV and MI model is stretching internal resources, let’s discuss how outsourcing can strengthen compliance and support your next milestone.
